TSH Biopharm Corporation Limited (TPEX:8432)
50.00
+0.30 (0.60%)
Aug 19, 2026, 1:30 PM CST
TSH Biopharm Corporation Revenue
TSH Biopharm Corporation had revenue of 330.69M TWD in the quarter ending June 30, 2026, with 22.80% growth. This brings the company's revenue in the last twelve months to 1.40B, up 12.99% year-over-year. In the year 2025, TSH Biopharm Corporation had annual revenue of 1.34B with 19.79% growth.
Revenue (ttm)
1.40B
Revenue Growth
+12.99%
P/S Ratio
1.37
Revenue / Employee
18.38M
Employees
76
Market Cap
1.91B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.34B | 220.81M | 19.79% |
| Dec 31, 2024 | 1.12B | 304.80M | 37.59% |
| Dec 31, 2023 | 810.92M | 69.85M | 9.43% |
| Dec 31, 2022 | 741.07M | 327.58M | 79.23% |
| Dec 31, 2021 | 413.48M | -34.38M | -7.68% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Maywufa Company | 1.64B |
| Prince Pharmaceutical | 1.06B |
| Excelsior Biopharma | 936.92M |
| Allied Biotech | 922.49M |
| DV Biomed | 795.19M |
| GeneFerm Biotechnology | 664.94M |
| Johnson Chemical Pharmaceutical Works | 569.57M |
| PhytoHealth | 143.43M |